Related Experiment Video
Updated: Jun 19, 2025
A Mouse Model to Assess Innate Immune Response to Staphylococcus aureus Infection
Published on: February 28, 2019
Hla protein expression and artesunate prevented mice from further damage caused by Staphylococcus aureus pneumonia
Weiwei Jiang1, Wen Luo1, Zimin Zhang2
1Department of Pharmacy, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China.
Abstract:
The laboratory standard MRSA strain WHO-2 and clinical isolate S1 were used to establish a pneumonia infection model. The results showed that methicillin increased the expression of Hla and PVL protein at subminimum inhibitory concentration, while artesunate decreased the secretion of Hla and PVL protein. Artesunate alone reduced hemolysin expression and reversed methicillin-induced increases in Hla and PVL proteins. In addition, the study found that the combination of artesunate and methicillin had the best therapeutic effect, with survival rates of 70 % and 40 % at seven days, respectively (corresponding to the WHO-2 and S1 strains). The combination treatment was able to reduce cell mortality, showing a 65 % and 46 % reduction in cell mortality, respectively. The study also found that the combination therapy decreased the expression of alpha-hemolysin and pantone valentin leukin in the culture medium and significantly reduced the activation of NF-kB. This is caused by a significant decrease in the expression of inflammatory factors.
Insights
This study reveals that combining artesunate and methicillin effectively treats MRSA pneumonia by reducing harmful toxins and inflammation. This combination therapy significantly improves survival rates and lowers cell mortality in pneumonia models.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant threat due to its resistance to antibiotics.
- Virulence factors like alpha-hemolysin (Hla) and Panton-Valentine leukocidin (PVL) contribute to MRSA pathogenicity.
- Novel therapeutic strategies are needed to combat MRSA infections.
Purpose of the Study:
- To investigate the therapeutic potential of artesunate in combination with methicillin against MRSA pneumonia.
- To evaluate the impact of these agents on MRSA virulence factor expression and host inflammatory responses.
Main Methods:
- Establishment of a pneumonia infection model using MRSA strains WHO-2 and S1.
- Assessment of Hla and PVL protein expression under different treatment conditions (methicillin, artesunate, combination).
- Evaluation of survival rates, cell mortality, and NF-kB activation in response to treatments.
Main Results:
- Methicillin alone increased Hla and PVL expression at sub-inhibitory concentrations.
- Artesunate alone decreased Hla and PVL secretion and reversed methicillin-induced increases.
- The combination of artesunate and methicillin demonstrated the highest therapeutic efficacy, significantly improving survival rates (70% for WHO-2, 40% for S1) and reducing cell mortality (65% and 46% reduction, respectively).
- Combination therapy suppressed alpha-hemolysin and PVL expression, reduced NF-kB activation, and decreased inflammatory factors.
Conclusions:
- Artesunate exhibits anti-virulence properties against MRSA, reducing key toxins.
- The combination of artesunate and methicillin offers a promising therapeutic approach for MRSA pneumonia, mitigating virulence and inflammation.
- This combination strategy warrants further clinical investigation for MRSA infection treatment.
